Effective September 1, 2026, Sanofi’s Executive Committee will comprise:François Roger, Executive Vice President, FinancePaulo Fontoura, Executive Vice President, Head of Research & DevelopmentManuela Buxo, Executive Vice President, Specialty CareThomas Triomphe, Executive Vice President, VaccinesThomas Grenier, Executive Vice President, General MedicinesBrendan O’Callaghan, Executive Vice President, Manufacturing & SupplyJamie Haney, Executive Vice President, General CounselVéronique Jaillet, Executive Vice President, Chief People Officer, ad interimEmmanuel Frenehard, Head of Digital and Audrey Duval, Head of Corporate Affairs and President of Sanofi France, will continue to report directly to Belén Garijo, Sanofi’s CEO. Thomas Triomphe will also assume responsibility for China, alongside his role as Executive Vice President, Vaccines. Olivier Charmeil, currently Executive Vice President, General Medicines, will transition to Strategic Projects Advisor to the CEO. Forward-looking statements are statements that are not historical facts. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.